Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zealand Pharma AS has the Financial Strength Rank of 9. It shows strong financial strength and is unlikely to fall into distressed situations.
Good Sign:
Zealand Pharma AS shows strong financial strength.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.
A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
Zealand Pharma AS's Interest Coverage for the quarter that ended in Jun. 2026 was 321.58.
Zealand Pharma AS's debt to revenue ratio for the quarter that ended in Jun. 2026 was 0.02.
As of today, Zealand Pharma AS's Altman Z-Score is 8.40.
Zealand Pharma AS (OTCPK:ZLDPF) Financial Strength Explanation
The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
Zealand Pharma AS has the Financial Strength Rank of 9. It shows strong financial strength and is unlikely to fall into distressed situations.
Zealand Pharma AS Financial Strength Related Terms
ZLDPF vs VRTX, REGN, MRNA: Financial Strength Comparison
For the Biotechnology subindustry, Zealand Pharma AS's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zealand Pharma AS Financial Strength vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Financial Strength distribution charts can be found below:
* The bar in red indicates where Zealand Pharma AS's Financial Strength falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Zealand Pharma AS has enough cash to cover all of its debt. Its financial situation is stable.
2. Debt to revenue ratio. The lower, the better.
Zealand Pharma AS's Debt to Revenue Ratio for the quarter that ended in Jun. 2026 is
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Zealand Pharma AS has a Z-score of 8.40, indicating it is in Safe Zones. This implies the Z-Score is strong.
Good Sign:
Altman Z-score of 8.4 is strong.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zealand Pharma AS (ZLDPF) has a Financial Strength of 9 as of Jun. 2026. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Zealand Pharma AS and its competitors. This is 29% above median its historical median of 7.00. Over the past decade, Zealand Pharma AS's Financial Strength has ranged from 3.00 to 10.00.
Is Zealand Pharma AS's Financial Strength too high?
Zealand Pharma AS's current Financial Strength of 9 is 29% above median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 10.00. Overall, Zealand Pharma AS has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's Financial Strength compare to VRTX and REGN?
Zealand Pharma AS's Financial Strength of 9 can be compared against companies in the Biotechnology industry. Historically, Zealand Pharma AS's own Financial Strength has ranged from 3.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Financial Strength for a Biotechnology company?
A good Financial Strength depends on the Biotechnology industry context. However, Financial Strength should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Financial Strength mean?
A high Financial Strength can signal that a stock is expensive relative to its fundamentals. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Zealand Pharma AS and its competitors. Zealand Pharma AS's current Financial Strength is 9, which is 29% above median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Based on GuruFocus' analysis, Zealand Pharma AS (ZLDPF) is currently considered Possible Value Trap. The stock's GF Value™ is $2,513.14, compared to a current price of $43.00 — trading 98.3% below its estimated fair value. The current Financial Strength is 9, which is 29% above median its 10-year median of 7.00. Zealand Pharma AS's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Financial Strength calculated?
Financial Strength is calculated from a company's financial statements. For Zealand Pharma AS (ZLDPF), the current Financial Strength is 9 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zealand Pharma AS (ZLDPF) Overvalued in 2026?
Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued.
The current stock price of $43.00 is trading 98.3% below its estimated GF Value™ of $2,513.14.
GuruFocus considers Zealand Pharma AS to be Possible Value Trap.
Key valuation signals for ZLDPF:
Financial Strength: 9 (29% above median its 10-year median of 7.00)
GF Value™: $2,513.14 vs. price of $43.00 (98.3% below fair value)
No single metric tells the full story. See the ZLDPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
63GF Score
Get the complete analysis for ZLDPF
Financial Strength is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLDPF has been successfully added to your 
